Matthew A. Lauber

Matthew A. Lauber is a Senior Director Portfolio Owner at Waters Corporation (Milford, USA).

Articles

The RNA polymerase II transcribing DNA into RNA. | Image Credit: © Juan Gärtner - stock.adobe.com

Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping

Thomas Menneteau;Balasubrahmanyam Addepalli;Tatiana Johnston;Christian Reidy;Matthew Gorton;Jennifer Bouchenna;Nick Pittman;Claire I. Butré ;Damien Mouvet;Laetitia Denbigh;Matthew A. Lauber;Arnaud Delobel

January 3rd 2025

New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this progress builds, the industry remains accountable for characterizing these molecules to meet the requirements of regulatory authorities.

3d render of dna structure, abstract background | Image Credit: © Giovanni Cancemi - stock.adobe.com

Pressure–Enhanced Liquid Chromatography as a Suitable Approach to Improve Selectivity for Large Molecule Separations

Honorine Lardeux;Davy Guillarme;Mateusz Imiołek;Szabolcs Fekete;Matthew A. Lauber

April 1st 2023

Pressure-enhanced liquid chromatography (PE-LC) offers a new approach for improving selectivity for large molecule separations. Examples shown here include short oligonucleotides in ion-pairing reversed-phase (IP-RP) liquid chromatography and larger nucleic acids in ion-exchange (IEX) chromatography.